When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BCLI - FDA panel to review BrianStorm's NurOwn therapy for ALS
Brainstorm Cell Therapeutics Inc.
2023-06-06 15:05:56 ET
BrainStorm Cell Therapeutics ( NASDAQ: BCLI ) said that a US Food and Drug Administration advisory committee is set to review its biologics license application on Sept. 27 for its stem cell therapy NurOwn for the treatment of amyotrophic lateral sclerosis, or ALS.
The FDA has an action date of Dec. 8 to make a decision on whether to approve the product for ALS, according to the company.